Across TCGA pan-cancer cohorts, HLA-C mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HLA-C data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher HLA-C mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated HLA-C expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where HLA-C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	37	view →
LSCC	OS	Quartile	II,III,IV	0.655	1.000	.009	22	view →
PDAC	DFS	Tertile	All	0.732	0.908	.013	8	view →
LUAD	DFS	Median	All	0.423	0.716	.024	6	view →
HNSC	DFS	Quartile	IV	0.936	0.691	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: HLA-C tumor-vs-normal RNA expression · all HLA-C data types